The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Combination therapy of intraarterial 5‐fluorouracil and systemic interferon‐alpha for advanced hepatocellular carcinoma with portal venous invasion
Open accessAbstract
BACKGROUND: Hepatocellular carcinoma (HCC) with portal venous invasion (PVI) has a very poor prognosis, with a median survival of 3 months and virtually no survival at 1 year. The combination of intraarterial 5‐fluorouracil (FU) and systemic interferon‐α (IFNα) was recently reported to be effective against HCC with PVI, but these were small pilot studies. METHODS: One hundred and sixteen patients with HCC with PVI received IFNα (5,000,000 U intramuscularly on Days 1, 3, and 5 of each week of treatment) and 5‐FU (500 mg into hepatic artery on Days 1‐5 of the first and second week of each 4‐week cycle). The therapy was either terminated at the end of the first cycle in cases with progressive disease, or continued for at least 3 cycles, when responses to treatment were evaluated by Eastern Cooperative Oncology Group criteria. The survival rate was compared with that of historical controls (n = 40). RESULTS: Nineteen (16%) patients showed complete response and another 42 (36%) showed partial response. Adverse events were limited to nausea and appetite loss. The survival rates at 12 and 24 months among overall patients were 34% and 18%, respectively, in contrast to 15% and 5% among the historical controls. Survival rates at 12 and 24 months were 81% and 59% among complete responders, respectively, and 43% and 18% among partial responders. CONCLUSION: The combination therapy with 5‐FU and IFN was safe, and substantially improved the survival rate among the complete responders. These results provide a rationale for future randomized controlled trials. Cancer 2006. © 2006 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847
Boring, C. C., Squires, T. S., & Tong, T. (1992) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.42.1.19 · Cited by 528
Roayaie, S., Frischer, J. S., Emre, S. H., Fishbein, T. M., Sheiner, P. A., Sung, M., Miller, C. M., & Schwartz, M. E. (2002) · Annals of Surgery · doi:10.1097/00000658-200204000-00012 · Cited by 390
Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients.
Shiina, S., Tagawa, K., Niwa, Y., Unuma, T., Komatsu, Y., Yoshiura, K., Hamada, E., Takahashi, M., Shiratori, Y., & Terano, A. (1993) · American Journal of Roentgenology · doi:10.2214/ajr.160.5.7682378 · Cited by 370
Self-citationPrimary liver cancer in Japan. Clinicopathologic features and results of surgical treatment.
(1990) · PubMed Central · Cited by 370
Tobe, T., Uchino, J., Endo, Y., Oto, M., Okamoto, E., Kojiro, M., Shikata, T., Tanikawa, K., Tsuzuki, T., Mizumoto, R., et al. (1994) · Cancer · doi:10.1002/1097-0142(19941115)74:10<2772::aid-cncr2820741006>3.0.co;2-v · Cited by 335
Changing incidence of hepatocellular carcinoma in Japan.
Okuda, K., Fujimoto, I., Hanai, A., & Urano, Y. (1987) · PubMed · Cited by 328
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
Llovet, J. M., Sala, M., Castells, L., Suarez, Y., Vilana, R., Bianchi, L., Ayuso, C., Vargas, V., Rodés, J., & Bruix, J. (2000) · Hepatology · doi:10.1002/hep.510310111 · Cited by 271
Shinagawa, T., Ohto, M., Kimura, K., Tsunetomi, S., Morita, M., Saisho, H., Tsuchiya, Y., Saotome, N., Karasawa, E., & Miki, M. (1984) · PubMed · Cited by 268
Hepatocellular Carcinoma and Cirrhosis: Results of Surgical Treatment in a European Series
Fuster, J., García-Valdecasas, J. C., Grande, L., Tabet, J., Bruix, J., Anglada, T., Taurá, P., Lacy, A. M., González, X., Vilana, R., et al. (1996) · Annals of Surgery · doi:10.1097/00000658-199603000-00011 · Cited by 227
Sakon, M., Nagano, H., Dono, K., Nakamori, S., Umeshita, K., Yamada, A., Kawata, S., Imai, Y., Iijima, S., & Monden, M. (2002) · Cancer · doi:10.1002/cncr.10246 · Cited by 202
Shiina, S., Teratani, T., Obi, S., Hamamura, K., Koike, Y., & Omata, M. (2002) · Oncology · doi:10.1159/000048278 · Cited by 183
Self-citationKoike, Y., Shiratori, Y., Sato, S., Obi, S., Teratani, T., Imamura, M., Hamamura, K., Imai, Y., Yoshida, H., Shiina, S., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.20237 · Cited by 131
Self-citationTreatment of Cancer of the Liver
Stehlin, J. S., de Ipolyi, P. D., Greeff, P. J., McGaff, C. J., Davis, B. R., & McNARY, L. (1988) · Annals of Surgery · doi:10.1097/00000658-198807000-00004 · Cited by 128
Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention
Shiratori, Y., Yoshida, H., & Omata, M. (2001) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.1.2.277 · Cited by 24
Self-citation
Cited by
Hepatocellular carcinoma with extrahepatic metastasis: Clinical features and prognostic factors
Uchino, K., Tateishi, R., Shiina, S., Kanda, M., Masuzaki, R., Kondo, Y., Goto, T., Omata, M., Yoshida, H., & Koike, K. (2011) · Cancer · doi:10.1002/cncr.25960 · Cited by 427
Self-citationKudo, M., Ueshima, K., Yokosuka, O., Ogasawara, S., Obi, S., Izumi, N., Aikata, H., Nagano, H., Hatano, E., Sasaki, Y., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30078-5 · Cited by 305
Self-citationKanda, T., Goto, T., Hirotsu, Y., Moriyama, M., & Omata, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061358 · Cited by 280
Self-citationChemotherapy for hepatocellular carcinoma: current status and future perspectives
Ikeda, M., Morizane, C., Ueno, M., Okusaka, T., Ishii, H., & Furuse, J. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx180 · Cited by 272
Metadata
- Authors
- Obi, S., Yoshida, H., Toune, R., Unuma, T., Kanda, M., Sato, S., Tateishi, R., Teratani, T., Shiina, S., & Omata, M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2006-03-24
- Volume
- 106
- Issue
- 9
- Pages
- 1990-1997
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2024802373
- Cited by
- 262
- References
- 17
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.